pp-206 Solution for injection
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Refractory angina in patients with no-option coronary artery disease (CAD) — patients not amenable to revascularisation
Clinical stage: Phase 2b; first patient dosed July 2025
Modality: Biological (adenoviral vector gene therapy — NBE)
Mechanism / Target: Adenoviral vector (AdVEGF-C) delivering VEGF-C (vascular endothelial growth factor-C) gene to ischaemic myocardium; promotes therapeutic myocardial angiogenesis and collateral vessel formation; reduces ischaemia in chronic no-option angina patients
Route / form: Epicardial injection (intraoperative) or catheter-based intramyocardial delivery
Differentiation: First VEGF-C gene therapy for refractory no-option angina;
Manufacturer #39343
US-based clinical-stage gene therapy company developing a first-in-class Rx treatment for a serious cardiovascular condition with limited treatment options. Proprietary approach promotes new blood-vessel growth in ischemic tissue. Advancing its lead program through clinical trials.
None